Clinical Trial Update: Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis [Phase 3]

View source ↗

Summary

An open-label Phase 3 extension trial evaluating roflumilast, a PDE-4 inhibitor, for the management of atopic dermatitis; the trial has completed and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Atopic Dermatitis Eczema | Phase 3 | Status: COMPLETED | Results posted: 2025-12-23